Please assess the completion status of the following clinical trial:

Trial Title: Systemic Inflammation and Obstructive Sleep Apnea Syndrome: Effect of Atorvastatin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women \> 18 years old~* Subjects diagnosed with OSAS (apnea/hypopnea index = AHI \> 30/h)~* Subjects with clinical ATH from grade I or II controlled with mono-therapy(140\<SAP\<180 mmHg and 90\<DAP\<110 mmHg)~Exclusion Criteria:~* Patients with a history of prior stroke or coronary ischemic disease~* Chronic respiratory disease (PaO2 \< 60 mmHg and/or PaCO2 \> 45 mmHg)~* Lung disease~* Hypothyroidism~* Statin treatment~* Antihypertensive treatment with more than one drug~* Pregnant or lactating women~* Alcohol consumption \> 3 units/day~* Treatment by itraconazole, ketoconazole, antiprotease, fibrates, antivitamin K, diltiazem, verapamil, erythromycin, clarithromycin, cyclosporin.~* Hypersensitivity to one of the drug compounds~* Patients with modified concomitant treatments during the 3 months before inclusion~* Potentially dangerous sleepiness~* Jobs at risk

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Stat/CPAP (Type: PLACEBO_COMPARATOR): Atorvastatin and CPAP treatments
- Stat/sham CPAP (Type: PLACEBO_COMPARATOR): Atorvastatin and sham CPAP treatments
- Placebo/CPAP (Type: SHAM_COMPARATOR): Placebo and CPAP treatments
- Placebo/sham CPAP (Type: ACTIVE_COMPARATOR): Placebo and sham CPAP treatments

Based on this trial design, predict the completion outcome and termination type (if applicable).